What is Shin Nippon Biomedical Laboratories, Ltd. (SNBL)?

Shin Nippon Biomedical Laboratories, Ltd. is a contract research organization (CRO) founded in Kagoshima City in 1957. It primarily supports pharmaceutical development by conducting non-clinical and clinical studies for pharmaceutical and biotechnology companies.

Why is SNBL expanding its research facilities?

The expansion is driven by increased demand from major European and American pharmaceutical companies, leading to the acquisition of preferred vendor agreements. The company anticipates further order growth and needs to increase its capacity.

What is the planned new facility called and where will it be located?

The new facility will be named the 'NHP Experimental Facility EU Experimental Building' and will be located in part of Miyano-ura Town, Kagoshima City.

When is the new facility expected to start operations?

The new facility is scheduled to begin operations in November 2027 (Reiwa 9).

What is the expected impact of this expansion on Kagoshima City?

The expansion is expected to promote new drug development globally from Kagoshima, create new jobs (85 new hires planned), and contribute significantly to the revitalization of the local economy.

CRO stands for Contract Research Organization. It is an organization that undertakes the operation and management of non-clinical and clinical studies for pharmaceutical companies, supporting their drug development process.

AI News NQ Analysis

Shin Nippon Biomedical Laboratories, Ltd. to Expand Research and Development Facilities! Location Agreement Signed with Kagoshima City!

NQ Score 57/100

AI Summary (NQ-processed)

Shin Nippon Biomedical Laboratories signs a location agreement with Kagoshima City to expand its research and development facilities, aiming for business growth.

AI analysis data is not yet available.

Frequently Asked Questions

Q: What is Shin Nippon Biomedical Laboratories, Ltd. (SNBL)?: A: Shin Nippon Biomedical Laboratories, Ltd. is a contract research organization (CRO) founded in Kagoshima City in 1957. It primarily supports pharmaceutical development by conducting non-clinical and clinical studies for pharmaceutical and biotechnology companies.
Q: Why is SNBL expanding its research facilities?: A: The expansion is driven by increased demand from major European and American pharmaceutical companies, leading to the acquisition of preferred vendor agreements. The company anticipates further order growth and needs to increase its capacity.
Q: What is the planned new facility called and where will it be located?: A: The new facility will be named the 'NHP Experimental Facility EU Experimental Building' and will be located in part of Miyano-ura Town, Kagoshima City.
Q: When is the new facility expected to start operations?: A: The new facility is scheduled to begin operations in November 2027 (Reiwa 9).
Q: What is the expected impact of this expansion on Kagoshima City?: A: The expansion is expected to promote new drug development globally from Kagoshima, create new jobs (85 new hires planned), and contribute significantly to the revitalization of the local economy.
Q: What is a CRO?: A: CRO stands for Contract Research Organization. It is an organization that undertakes the operation and management of non-clinical and clinical studies for pharmaceutical companies, supporting their drug development process.